IGFBP7 and acute kidney injury: In addition, we did not assess two biomarkers recently approved by the Food and Drug Administration for AKI diagnosis, namely insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinases-2 [28–30].